122 related articles for article (PubMed ID: 15450948)
1. Effective metabolism and long intracellular half life of the anti-hepatitis B agent adefovir in hepatic cells.
Ray AS; Vela JE; Olson L; Fridland A
Biochem Pharmacol; 2004 Nov; 68(9):1825-31. PubMed ID: 15450948
[TBL] [Abstract][Full Text] [Related]
2. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.
Delaney WE; Ray AS; Yang H; Qi X; Xiong S; Zhu Y; Miller MD
Antimicrob Agents Chemother; 2006 Jul; 50(7):2471-7. PubMed ID: 16801428
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection.
Sokal EM; Kelly D; Wirth S; Mizerski J; Dhawan A; Frederick D
J Clin Pharmacol; 2008 Apr; 48(4):512-7. PubMed ID: 18276803
[TBL] [Abstract][Full Text] [Related]
4. Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression.
Leemans WF; Janssen HL; Niesters HG; de Man RA
J Viral Hepat; 2008 Feb; 15(2):108-14. PubMed ID: 18184193
[TBL] [Abstract][Full Text] [Related]
5. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B.
Jonas MM; Kelly D; Pollack H; Mizerski J; Sorbel J; Frederick D; Mondou E; Rousseau F; Sokal E
Hepatology; 2008 Jun; 47(6):1863-71. PubMed ID: 18433023
[TBL] [Abstract][Full Text] [Related]
6. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
[TBL] [Abstract][Full Text] [Related]
7. Adefovir dipivoxil in chronic hepatitis B: history and current uses.
Segovia MC; Chacra W; Gordon SC
Expert Opin Pharmacother; 2012 Feb; 13(2):245-54. PubMed ID: 22242973
[TBL] [Abstract][Full Text] [Related]
8. Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B.
Reddy KR; Matelich MC; Ugarkar BG; Gómez-Galeno JE; DaRe J; Ollis K; Sun Z; Craigo W; Colby TJ; Fujitaki JM; Boyer SH; van Poelje PD; Erion MD
J Med Chem; 2008 Feb; 51(3):666-76. PubMed ID: 18173234
[TBL] [Abstract][Full Text] [Related]
9. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Marcellin P; Chang TT; Lim SG; Tong MJ; Sievert W; Shiffman ML; Jeffers L; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL;
N Engl J Med; 2003 Feb; 348(9):808-16. PubMed ID: 12606735
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, anti-HBV activity and renal cell toxicity evaluation of mixed phosphonate prodrugs of adefovir.
Fu XZ; Ou Y; Pei JY; Liu Y; Li J; Zhou W; Lan YY; Wang AM; Wang YL
Eur J Med Chem; 2012 Mar; 49():211-8. PubMed ID: 22305613
[TBL] [Abstract][Full Text] [Related]
11. Effects of 1α,25-dihydroxyvitamin D3 on transport and metabolism of adefovir dipivoxil and its metabolites in Caco-2 cells.
Maeng HJ; Chapy H; Zaman S; Pang KS
Eur J Pharm Sci; 2012 Jun; 46(3):149-66. PubMed ID: 22387228
[TBL] [Abstract][Full Text] [Related]
12. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
Lee JM; Park JY; Kim DY; Nguyen T; Hong SP; Kim SO; Chon CY; Han KH; Ahn SH
Antivir Ther; 2010; 15(2):235-41. PubMed ID: 20386079
[TBL] [Abstract][Full Text] [Related]
13. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.
Westland CE; Yang H; Delaney WE; Gibbs CS; Miller MD; Wulfsohn M; Fry J; Brosgart CL; Xiong S;
Hepatology; 2003 Jul; 38(1):96-103. PubMed ID: 12829991
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
[TBL] [Abstract][Full Text] [Related]
15. [Recent advances in the treatment of the hepatitis HBV-related. Effectiveness and tolerability of adefovir dipivoxil].
Palumbo E
Recenti Prog Med; 2007 Apr; 98(4):237-8. PubMed ID: 17547362
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus kinetics and mathematical modeling.
Perelson AS; Ribeiro RM
Semin Liver Dis; 2004; 24 Suppl 1():11-6. PubMed ID: 15192796
[TBL] [Abstract][Full Text] [Related]
17. Liquid oral suspension adefovir dipivoxil (GS-02-526): an update on treatments for hepatitis B infection.
Chen EQ; Shi Y; Wu DB; Tang H
Expert Rev Anti Infect Ther; 2014 Aug; 12(8):919-28. PubMed ID: 24927815
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous quantitation of the nucleotide analog adefovir, its phosphorylated anabolites and 2'-deoxyadenosine triphosphate by ion-pairing LC/MS/MS.
Vela JE; Olson LY; Huang A; Fridland A; Ray AS
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Apr; 848(2):335-43. PubMed ID: 17101307
[TBL] [Abstract][Full Text] [Related]
19. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Arterburn S; Xiong S; Currie G; Brosgart CL;
N Engl J Med; 2005 Jun; 352(26):2673-81. PubMed ID: 15987916
[TBL] [Abstract][Full Text] [Related]
20. [A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period].
Yang Q; Gong ZJ; Hu DF
Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):515-9. PubMed ID: 19912686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
